Precision BioSciences Inc. reported total revenues of less than $0.1 million for the third quarter ended September 30, 2025, compared to $0.6 million in the same period in 2024, primarily due to reduced billable effort under the Novartis Agreement. Research and development expenses were $13.4 million, up from $13.1 million in the prior year quarter, mainly due to increased investment in the PBGENE-DMD program, partially offset by decreases in the PBGENE-HBV and PBGENE-3243 programs. As of September 30, 2025, the company held approximately $71.2 million in cash, cash equivalents, and restricted cash. Precision BioSciences expects its current cash resources, along with anticipated near-term cash from CAR T transactions and operational efficiencies, to fund the company into the second half of 2027. During the quarter, the company commenced dosing in Cohort 3 of the ELIMINATE-B trial for PBGENE-HBV, advanced an IND filing for PBGENE-DMD expected by the end of 2025, and implemented expense reductions to extend its cash runway.
Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Precision BioSciences Inc. published the original content used to generate this news brief via EDGAR, the Electronic Data Gathering, Analysis, and Retrieval system operated by the U.S. Securities and Exchange Commission (Ref. ID: 0001628280-25-047920), on November 03, 2025, and is solely responsible for the information contained therein.
Comments